/**/ RNS Number : 0116E IQ-AI Limited 22 February 2024   IQ-AI Limited (“IQ-AI” or the “Company”) Placing and Broker Option ​ IQAI Limited (the “Company” or “IQAI”), the parent company of Wisconsin-based Imaging Biometrics, LLC (“IB”), which is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively,

/**/ RNS Number : 6911C IQ-AI Limited 09 February 2024   IQ-AI Ltd (“IQ-AI” or the “Company”)   FDA Application Update   Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), reports that it will modify and resubmit its application for Pediatric Rare Disease (PRD) Designation, in response to a letter from

/**/ RNS Number : 8587B IQ-AI Limited 02 February 2024   IQ-AI Ltd (“IQ-AI” or the “Company”)   IB awarded a $100,000 grant by the Musella Foundation Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), announces that it has been awarded a $100,000 grant by the Musella Foundation For Brain

/**/ RNS Number : 4625A IQ-AI Limited 22 January 2024   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to

/**/ RNS Number : 6148Z IQ-AI Limited 15 January 2024   IQ-AI Ltd (“IQ-AI” or the “Company”)   Director Dealings and Conversion of Convertible Loan Notes IQ-AI Ltd has received convertible loan note conversion notices from Trevor Brown, the CEO of IQ-AI, and Micheal Schmainda, a director of IQ-AI. Trevor Brown is converting a total

/**/ RNS Number : 6147Z IQ-AI Limited 15 January 2024   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares

/**/ RNS Number : 1417Z IQ-AI Limited 10 January 2024   IQ-AI Ltd (“IQ-AI” or the “Company”) Imaging Biometrics Launching an Expanded Access Program for Oral GaM    Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI, OTCBB: IQAIF), is launching an intermediate population cohort expanded access program (EAP) for oral

/**/ RNS Number : 3492X IQ-AI Limited 19 December 2023   IQ-AI Ltd (“IQ-AI” or the “Company”)   Imaging Biometrics granted FDA “Fast-Track” Dec 19, 2023 – Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQ-AI Ltd (LSE: IQAI), is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted “Fast-Track”

/**/ RNS Number : 7354V IQ-AI Limited 05 December 2023   IQ-AI Ltd (“IQ-AI” or the “Company”) IQ-AI Announces Positive Interim Phase 1 Results On-going trial to study the safety of oral gallium maltolate in relapsed GBM patients ·    All three planned dose levels tested to date continue to exhibit favorable safety and tolerability ·   

/**/ RNS Number : 0230U IQ-AI Limited 20 November 2023   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to